vimarsana.com

Latest Breaking News On - Talzenna - Page 1 : vimarsana.com

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

Pfizer : FDA Approves Talzenna-Xtandi Combination To Treat Prostate Cancer

Pfizer (PFE) said that the U.S. Food and Drug Administration has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), for the treatment of adult patients with homologous recombination repair or HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

Pfizer Reports Positive Data From Phase 3 Trial Of Talzenna/Xtandi Combo

NEW YORK CITY (dpa-AFX) - Pfizer (PFE) Thursday reported positive results from the Phase 3 TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with

Pfizer Reports Positive Data, Priority Review for Talzenna/Xtandi Combo

By Colin Kellaher Pfizer Inc. on Thursday said a Phase 3 study combining its breast-cancer drug Talzenna with its prostate-cancer drug Xtandi showed a 37% reduction in the risk of disease. | February 16, 2023

Pfizer Reports Positive Topline Results From Phase 3 TALZENNA Trial

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced Tuesday positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib) plus XTANDI in men with metastatic castration-resistant

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.